Welcure Drugs Reports Strong Sales Growth and Highest Profit in Five Quarters
Welcure Drugs & Pharmaceuticals has announced its financial results for the quarter ending March 2025, highlighting significant growth in net sales, which reached Rs 22.09 crore. The company also reported its highest profit after tax in five quarters at Rs 2.54 crore, alongside a peak earnings per share of Rs 0.23. However, a large portion of profit before tax is attributed to non-operating income, raising sustainability concerns.
Welcure Drugs & Pharmaceuticals has recently reported its financial results for the quarter ending March 2025, showcasing notable developments within the company. The evaluation changes reflect a significant adjustment in its score, moving to 16 from 8 over the past three months.The financial data indicates a remarkable performance in net sales, which reached Rs 22.09 crore, demonstrating a substantial year-on-year growth. This positive sales trend suggests a strong market presence for Welcure Drugs. Additionally, the company achieved its highest profit after tax (PAT) in the last five quarters, amounting to Rs 2.54 crore, indicating a favorable near-term PAT trend. Furthermore, earnings per share (EPS) also reached a peak of Rs 0.23, highlighting an increase in profitability and enhanced earnings for shareholders.
However, it is important to note that a significant portion of the company's profit before tax is derived from non-operating income, which constitutes 75.20%. This reliance on income from non-business activities raises concerns regarding the sustainability of its business model.
For further insights, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
